

## Number of shares and votes in Medivir AB on 27 February 2026

**Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during February 2026 as a result of the directed issue to Carl Bennet AB resolved on by Medivir on 5 February 2026. The issue has been previously announced through a separate press release. The new issue resulted in an increase of 90,000,000 ordinary shares.**

Today, the last trading day of the month, there are in total 541,121,383 shares in Medivir, of which 538,671,220 ordinary shares and 2,450,163 class C-shares, which together carry 538,916,236.3 votes. One ordinary share entitles to one (1) vote and one class C-share entitles to one tenth (1/10) of a vote.

**For additional information, please contact;**

Magnus Christensen  
Chief Financial Officer  
Medivir AB  
Phone: +46 8 5468 3100  
Email: [Magnus.Christensen@medivir.com](mailto:Magnus.Christensen@medivir.com)

*This information is information that Medivir is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-02-27 08:30 CET.*

### **About Medivir**

Medivir develops innovative therapies targeting areas of high unmet medical need. Its drug candidates focus on indications where current treatment options are limited or non-existent, offering the potential to deliver meaningful improvements for patients. Medivir's two lead programs are fostrox, a precision chemotherapy designed to selectively target liver cancer cells while minimizing side effects, and MIV-711, aimed at treating Osteogenesis Imperfecta (brittle bone disease). Both candidates have blockbuster potential, representing significant value creation opportunities for Medivir's shareholders and affected patients. Collaborations and partnerships play a key role in Medivir's business model, with drug development conducted either in-house or in partnership. Medivir (Nasdaq Stockholm: MVIR) is listed on the Small Cap segment of Nasdaq Stockholm. More information is available at [www.medivir.com](http://www.medivir.com)